Interim Report Q2 2026
Interim report 2026, January 1–June 30
Net revenue growth remained weak during the quarter, impacted by cautious investment decisions in capital equipment within certain product categories and by geopolitical uncertainty. In the second quarter, net revenue decreased by 5.0 percent in constant currency. At the same time, order intake increased by 1.8 percent in constant currency, which gives us confidence for the coming periods. Cash flow from operating activities improved by almost 160 percent, driven by lower financing costs and improved working capital.
April–June 2026
Net revenue was SEK 372.0 million (396.1), a decrease of 6.1%, of which -5.0% was organic and
-1.1% currency effects
Orders received was SEK 407.2 million (404.7), an increase of 0.6%, of which +1.8% was organic and
-1.2% currency effects
EBITA was SEK 41.8 million (61.3), a decrease of 31.9%
Operating profit (EBIT) was SEK 9.1 million (50.2)
Loss for the period was SEK -14.0 million (-82.8) and adjusted profit for the period was SEK 8.8 million (10.8)
Basic earnings per share amounted to SEK -0.02 (-0.14)
Operating cash flow was SEK 43.5 million (16.8), an increase of 158.5%
January–June 2026
Net revenue was SEK 729.4 million (820.1), a decrease of 11.1%, of which -6.1% was organic and
-5.0% currency effects
Orders received was SEK 820.0 million (807.1), an increase of 1.6%, of which +7.4% was organic and
-5.8% currency effects
EBITA was SEK 87.3 million (136.6), a decrease of 36.1%
Operating profit (EBIT) was SEK 48.1 million (119.5)
Loss for the period was SEK -5.5 million (-57.1) and adjusted profit for the period was SEK 22.9 million (36.5).
Basic earnings per share amounted to SEK -0.01 (-0.14)
Operating cash flow was SEK 84.7 million (53.4), an increase of 58.7%
CEO’s comment
Stable order intake and good cash generation
In the second quarter of 2026, net revenue decreased by 6.1 percent compared to the same quarter last year. In constant currency, net revenue decreased by 5.0 percent, with which we are not satisfied. We continue to see cautious investment decisions regarding capital equipment in parts of the laboratory market. Our operations in the Middle East have been strongly impacted by the situation in the region, with disruptions in maritime transport, both for purchases of raw materials and deliveries to customers. Despite the difficult situation, we have continued to be able to deliver, but with limited capacity, which has had a negative impact on net revenue and earnings. Order intake continued to be stable, with a slight increase compared to the same quarter last year. With organic order growth of 7.4 percent year-to-date, we have a positive outlook for the coming periods.
EBITA amounted to SEK 41.8 million (61.3), corresponding to an EBITA margin of 11.2 percent (15.5). The negative earnings trend is mainly explained by lower volumes, a changed product mix in the diabetes business, lower demand for investment-related laboratory equipment and the impact of the situation in the Middle East. The loss for the period was impacted by impairment of trademarks related to a business that is in the process of being wound down.
Cash flow from operating activities amounted to SEK 43.5 million (16.8), which shows good cash generation even though net revenue and earnings do not meet our expectations. ADDvise continues to develop the offering in our companies, with a focus on profitability, customer benefit and long-term competitiveness.
ADDvise has been part of the Amplex Group since earlier this year after Amplex AB acquired and took control of all shares in ADDvise. ADDvise continues to operate as a sub-group and a business area within the Amplex Group. As an adjustment to the Amplex Group, ADDvise will change to a non-calendar financial year running from October to September. This means that the next report will be the year-end report for the shortened financial year January–September 2026.
Our financial position remains stable. The equity ratio at the end of the period was 39.3 (35.9) percent and the Group fulfilled all covenant requirements in its financing agreements.
We continue to work to strengthen profitability, improve cash flow and reduce indebtedness. At the same time, we continue to work with selective acquisitions as part of our long-term strategy to grow both through acquisitions and organically.
We summarise a quarter where net revenue and earnings did not meet our expectations. Our companies have the capacity to perform at a higher level. At the same time, I am pleased with the stable cash flow and order intake, which gives us the conditions to deliver on our strategy and our long-term goals. Together with our employees, companies and our owner, we continue to improve, extend and save people’s lives.
Staffan Torstensson, CEO
For further information, please contact:
Staffan Torstensson, CEO
+46 (0) 70-433 20 19
staffan.torstensson@addvisegroup.se
Johan Irwe, CFO
+46 (0) 73-731 26 11
ADDvise’s financial reports are available on ADDvise’s website, https://www.addvisegroup.com/investor-relations/financial-and-annual-reports/
The interim report is published in Swedish and English. The Swedish version represents the original.
About ADDvise
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.6 billion. Since 2026, ADDvise is a business area within the privately owned Swedish group Amplex AB. More information is available at www.addvisegroup.com.